
The PT-141 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of PT-141 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.
For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.
PT-141, also known as bremelanotide, is a synthetic peptide that acts on melanocortin receptors in the central nervous system. It has been studied primarily in relation to sexual response and disorders of sexual desire. In the United States, bremelanotide is approved for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Important Notice
- This analysis is specifically intended for PT-141. It does not automatically screen the sample for other melanocortin-related peptides, degradation products, contaminants, or undeclared substances.
- For lyophilised samples, one whole unopened vial containing lyophilisate is required.
- Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.
- The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.
The following optional laboratory services are available:
